Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | MMP1 | P03956 | 2/20 | 0.31 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | MMP9 | P14780 | 2/20 | 0.31 |
| ▸ | MMP8 | P22894 | 2/20 | 0.31 |
| ▸ | MMP13 | P45452 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9398166 | 0.90 | CA2 (0.39) | KDM4ETSHRTDP1CA2CA1 | |
| SCHEMBL5566604 | 0.86 | KDM4E (0.37) | KDM4ETSHRTDP1CA2CA1 | |
| SCHEMBL37506 | 0.85 | KDM4E (0.40) | KDM4ETSHRTDP1 | |
| SCHEMBL6536446 | 0.85 | KDM4E (0.40) | KDM4ETSHRTDP1 | |
| Sulfuric Acid SCHEMBL22118762 | 0.84 | KDM4E (0.40) | KDM4ETSHRTDP1CA2CA1 | |
| Sulfuric Acid SCHEMBL21876328 | 0.84 | KDM4E (0.40) | KDM4ETSHRTDP1CA2CA1 | |
| SCHEMBL21880000 | 0.82 | KDM4E (0.31) | KDM4ETSHRTDP1 | |
| Trifluoromethanesulfonic Acid SCHEMBL9146130 | 0.82 | KDM4E (0.39) | KDM4ETSHRTDP1CA2CA1 | |
| Iodide SCHEMBL11068952 | 0.82 | KDM4E (0.39) | KDM4ETSHRTDP1 | |
| Ammonia Solution, Strong SCHEMBL956721 | 0.82 | KDM4E (0.39) | KDM4ETSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028070-B2 | Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2021-06-08 | — | — | US | disclosed |
| US-20200262816-A1 | ISOINDOLINE OR ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2020-08-20 | — | — | US | disclosed |
| EP-3464281-B1 | MUTANT IDH1 INHIBITORS | LILLY CO ELI (US) | 2020-07-08 | — | — | EP | disclosed |
| US-10696665-B2 | Mutant IDH1 inhibitors | ELI LILLY AND COMPANY (US) | 2020-06-30 | — | — | US | disclosed |
| US-10689364-B2 | Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2020-06-23 | — | — | US | disclosed |
| WO-2020084854-A1 | FLUORINATED IMIDE SALT COMPOUND AND SURFACTANT | 三菱マテリアル電子化成株式会社 | 2020-04-30 | — | — | WO | disclosed |
| US-20190292175-A1 | MUTANT IDH1 INHIBITORS | ELI LILLY AND COMPANY | 2019-09-26 | — | — | US | disclosed |
| EP-3464281-A1 | MUTANT IDH1 INHIBITORS | Eli Lilly and Company (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-3024826-B1 | NEW ISOINDOLINE OR ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2018-11-14 | — | — | EP | disclosed |
| US-20180002313-A1 | ISOINDOLINE OR ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2018-01-04 | — | — | US | disclosed |
| WO-2008067481-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | GENENTECH, INC. | 2008-04-10 | — | — | US | disclosed |
| US-20080081821-A1 | AZA-benzothiophenyl compounds and methods of use | GENENTECH, INC. | 2008-04-03 | — | — | US | disclosed |
| WO-2008024724-A1 | AZA-BENZOTHIOPHENYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024725-A1 | AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| US-6667377-B2 | Having pendant groups containing fluorosulfonyl methide or fluorosulfonyl imide derivatives and univalent metal salts thereof; electrochemical applications such as batteries, fuel cells, electrolysis cells | E. I. DU PONT DE NEMOURS AND COMPANY | 2003-12-23 | — | — | US | disclosed |
| EP-1060200-B1 | SUBSTANTIALLY FLUORINATED IONOMERS | DU PONT (US) | 2003-01-15 | — | — | EP | disclosed |
| US-20020045713-A1 | Substantially fluorinated ionomers | DUPONT POLYMERS, INC. | 2002-04-18 | — | — | US | disclosed |
| EP-1060200-A1 | SUBSTANTIALLY FLUORINATED IONOMERS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-12-20 | — | — | EP | disclosed |
| WO-1999045048-A1 | SUBSTANTIALLY FLUORINATED IONOMERS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081821-A1 | AZA-benzothiophenyl compounds and methods of use | MKI67, CDKN1A, MAP3K1 | KDM4E 190/4885TSHR 3976/4885TDP1 569/4885 |
| US-10696665-B2 | Mutant IDH1 inhibitors | IDH1, IDH3B, IDH3A | KDM4E 978/4885TSHR 4122/4885TDP1 1902/4885 |
| US-20190292175-A1 | MUTANT IDH1 INHIBITORS | IDH1, IDH3B, IDH3A | KDM4E 978/4885TSHR 4122/4885TDP1 1902/4885 |
| US-20180002313-A1 | ISOINDOLINE OR ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BAX, CASP7, CASP3 | KDM4E 3156/4885TSHR 3185/4885TDP1 897/4885 |
| US-20200262816-A1 | ISOINDOLINE OR ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BAX, RECQL, CASP7 | KDM4E 3137/4885TSHR 3040/4885TDP1 1009/4885 |
| US-20080085886-A1 | Anticancer and/or antiinflammatory activity, MEK (MAP kinase kinase) inhibitors; for example, 3-(2-Fluoro-4-iodo-phenylamino)-furo[3,2-c]pyridine-2-carboxylic acid ((R)-2,3-dihydroxy-propoxy)-amide | MAP3K2, MAP3K1, MAP2K2 | KDM4E 1257/4885TSHR 3224/4885TDP1 2129/4885 |
| US-10689364-B2 | Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them | BAX, CASP7, CASP3 | KDM4E 3156/4885TSHR 3185/4885TDP1 897/4885 |
| US-11028070-B2 | Isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them | BAX, RECQL, CASP7 | KDM4E 3137/4885TSHR 3040/4885TDP1 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.